IAM
NKTR icon

Iridian Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Iridian Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.71M Buy
38,802
+7,482
+24% +$547K 0.93% 25
2026
Q1 		$2.25M Buy
31,320
+21,592
+222% +$1.23M 0.91% 29
2025
Q4 		$411K Buy
+9,728
New +$544K 0.15% 41

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Iridian Asset Management's NKTR Position: Q2 2026 in Review

Iridian Asset Management increased its Nektar Therapeutics (NKTR) stake by 24% in Q2 2026, buying an estimated $547K and bringing the position to 38,802 shares worth $2.71M. The position accounts for 0.93% of the portfolio, ranked #25.

Iridian Asset Management first reported a position in NKTR in Q4 2025 and has held it in 3 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Iridian Asset Management held 38,802 shares of Nektar Therapeutics worth $2.71M as of Q2 2026.
  • Iridian Asset Management bought 7,482 Nektar Therapeutics shares in Q2 2026, an estimated $547K.
  • Nektar Therapeutics made up 0.93% of Iridian Asset Management's portfolio in Q2 2026, its #25 holding.
  • Iridian Asset Management first reported a position in Nektar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Iridian Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.